Intervention Review

Ziprasidone for schizophrenia and severe mental illness

  1. Anne-Marie Bagnall1,*,
  2. Jos Kleijnen2,
  3. Maria Leitner3,
  4. Ruth Lewis4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 12 MAY 2010

Assessed as up-to-date: 30 AUG 2000

DOI: 10.1002/14651858.CD001945

Database Title

Additional Information

How to Cite

Bagnall AM, Kleijnen J, Leitner M, Lewis R. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD001945. DOI: 10.1002/14651858.CD001945.

Author Information

  1. 1

    Leeds Metropolitan University, Faculty of Health, Leeds, UK

  2. 2

    York, UK

  3. 3

    University of Liverpool, Faculty of Medicine, Liverpool, UK

  4. 4

    Cardiff University, Department of Primary Care and Public Health, Wrexham, UK

*Anne-Marie Bagnall, Faculty of Health, Leeds Metropolitan University, Calverley Street, Leeds, LS1 3HE, UK. A.Bagnall@leedsmet.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 12 MAY 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (57K)Standard (330K)Full (685K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via Athens http://onlinelibrary.wiley.com/athens or other institutional login options http://onlinelibrary.wiley.com/login-options .
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Summary (57K)Standard (330K)Full (685K)